Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 176

1.

Genomic loss of heterozygosity and survival in the REAL3 trial.

Smyth EC, Cafferkey C, Loehr A, Waddell T, Begum R, Peckitt C, Harding TC, Nguyen M, Okines AF, Raponi M, Rao S, Watkins D, Starling N, Middleton GW, Wadsley J, Mansoor W, Crosby T, Wotherspoon A, Chau I, Cunningham D.

Oncotarget. 2018 Nov 30;9(94):36654-36665. doi: 10.18632/oncotarget.26336. eCollection 2018 Nov 30.

2.

Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.

Augustine T, Maitra R, Zhang J, Nayak J, Goel S.

Invest New Drugs. 2019 Jan 5. doi: 10.1007/s10637-018-00717-9. [Epub ahead of print]

PMID:
30612311
3.

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.

Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, Lamb A, Hénon C, Dorvault N, Rouanne M, Marlow R, Bajrami I, Cardeñosa ML, Konde A, Besse B, Ashworth A, Pettitt SJ, Haider S, Marabelle A, Tutt AN, Soria JC, Lord CJ, Postel-Vinay S.

J Clin Invest. 2018 Dec 27. pii: 123319. doi: 10.1172/JCI123319. [Epub ahead of print]

4.

PARP inhibitors in ovarian cancer.

Franzese E, Centonze S, Diana A, Carlino F, Guerrera LP, Di Napoli M, De Vita F, Pignata S, Ciardiello F, Orditura M.

Cancer Treat Rev. 2018 Dec 4;73:1-9. doi: 10.1016/j.ctrv.2018.12.002. [Epub ahead of print] Review.

PMID:
30543930
5.

Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.

Kurnit KC, Coleman RL, Westin SN.

Curr Treat Options Oncol. 2018 Nov 15;19(12):1. doi: 10.1007/s11864-018-0572-7. Review.

PMID:
30535808
6.

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.

Faraoni I, Graziani G.

Cancers (Basel). 2018 Dec 4;10(12). pii: E487. doi: 10.3390/cancers10120487. Review.

7.

Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.

Guy H, Walder L, Fisher M.

Pharmacoeconomics. 2018 Nov 27. doi: 10.1007/s40273-018-0745-z. [Epub ahead of print]

PMID:
30478649
8.

Loss of the p12 subunit of DNA polymerase delta leads to a defect in HR and sensitization to PARP inhibitors.

Zhang S, Chao HH, Wang X, Zhang Z, Lee EYC, Lee MYWT.

DNA Repair (Amst). 2019 Jan;73:64-70. doi: 10.1016/j.dnarep.2018.11.003. Epub 2018 Nov 13.

PMID:
30470508
9.

Targeted treatment of advanced ovarian cancer: spotlight on rucaparib.

Pearre DC, Tewari KS.

Ther Clin Risk Manag. 2018 Nov 2;14:2189-2201. doi: 10.2147/TCRM.S149248. eCollection 2018. Review.

10.

How safe is rucaparib in ovarian cancer?

Cosgrove CM, O'Malley DM.

Expert Opin Drug Saf. 2018 Nov 19. doi: 10.1080/14740338.2018.1550067. [Epub ahead of print]

PMID:
30449210
11.

Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.

Xiao JJ, Nowak D, Ramlau R, Tomaszewska-Kiecana M, Wysocki PJ, Isaacson J, Beltman J, Nash E, Kaczanowski R, Arold G, Watkins S.

Clin Transl Sci. 2018 Nov 14. doi: 10.1111/cts.12600. [Epub ahead of print]

PMID:
30427584
12.

Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer.

Harold JA, Free SC, Bradley WH.

Gynecol Oncol Rep. 2018 Oct 28;26:91-93. doi: 10.1016/j.gore.2018.10.011. eCollection 2018 Nov.

13.

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM.

Cancer Discov. 2018 Nov 13. pii: CD-18-0715. doi: 10.1158/2159-8290.CD-18-0715. [Epub ahead of print]

PMID:
30425037
14.

Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.

Mullen MM, Kuroki LM, Thaker PH.

Gynecol Oncol. 2018 Nov 5. pii: S0090-8258(18)31306-4. doi: 10.1016/j.ygyno.2018.10.023. [Epub ahead of print] Review.

PMID:
30409489
15.

Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer.

Romeo M, Pardo JC, Martínez-Cardús A, Martínez-Balibrea E, Quiroga V, Martínez-Román S, Solé F, Margelí M, Mesía R.

Int J Mol Sci. 2018 Oct 19;19(10). pii: E3249. doi: 10.3390/ijms19103249. Review.

16.

Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.

Mukhopadhyay A, Drew Y, Matheson E, Salehan M, Gentles L, Pachter JA, Curtin NJ.

Biochem Pharmacol. 2018 Oct 17. pii: S0006-2952(18)30432-5. doi: 10.1016/j.bcp.2018.10.011. [Epub ahead of print]

PMID:
30342021
17.

PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.

Liposits G, Loh KP, Soto-Perez-de-Celis E, Dumas L, Battisti NML, Kadambi S, Baldini C, Banerjee S, Lichtman SM.

J Geriatr Oncol. 2018 Oct 14. pii: S1879-4068(18)30314-X. doi: 10.1016/j.jgo.2018.10.008. [Epub ahead of print] Review.

PMID:
30333088
18.

The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.

Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cucè M, Grillone F, Salvino A, Barbieri V, Russo A, Tassone P, Tagliaferri P.

Crit Rev Oncol Hematol. 2018 Nov;131:83-89. doi: 10.1016/j.critrevonc.2018.08.011. Epub 2018 Sep 3. Review.

PMID:
30293710
19.
20.

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.

Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL.

Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z.

Supplemental Content

Loading ...
Support Center